Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MT-6402

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Molecular Templates

Drug class:

PD-L1 inhibitor

Related drugs:

‹

atezolizumab (236)

durvalumab (199)

benmelstobart (12)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

cosibelimab-ipdl (0)

›

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	MT-6402 Sensitive: B - Late Trials MT-6402 Sensitive : B	MT-6402 Sensitive: B - Late Trials MT-6402 Sensitive : B
HLA-A*02 + PD-L1 expression	Solid Tumor	HLA-A*02 + PD-L1 expression	Solid Tumor	MT-6402 Sensitive: C3 – Early Trials MT-6402 Sensitive : C3	MT-6402 Sensitive: C3 – Early Trials MT-6402 Sensitive : C3